<DOC>
	<DOCNO>NCT00973505</DOCNO>
	<brief_summary>The purpose study investigate relationship side effect ( especially arthralgia arthritis ) appear patient prescribed aromatase inhibitor ( AI ) CYP19 genetic polymorphism .</brief_summary>
	<brief_title>CYP19 Genetic Polymorphism &amp; Aromatase Inhibitor ( AI )</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Arthralgia</mesh_term>
	<mesh_term>Aromatase Inhibitors</mesh_term>
	<mesh_term>Anastrozole</mesh_term>
	<mesh_term>Letrozole</mesh_term>
	<criteria>1 . The patient must sign informed consent . 2 . The patient must sign informed consent genetic screening test . 3 . The patient must 18 year old 80 year old make decision independently . 4 . The patient must postmenopause status . 5 . The patient stage 1,2 3 breast cancer . 6 . The test result estrogen receptor progesterone receptor positive , patient take medication AI ( Aromatase Inhibitor ) . 1 . The patient premenopause status . 2 . The test result serum FSH level 30mU/ml . 3 . The test result hormone receptor ( ER &amp; PR ) negative unknown . 4 . Patient 's breast cancer stage 4 systemic metastatics .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>September 2009</verification_date>
	<keyword>Breast neoplasm</keyword>
	<keyword>Aromatase inhibitor</keyword>
	<keyword>Genetic polymorphism</keyword>
	<keyword>Arthralgia</keyword>
	<keyword>Arthritis</keyword>
</DOC>